As the risks associated with ART have decreased because of more potent and tolerable
drug combinations, the risk-benefit ratio of initiating ART has shifted toward beginning therapy
at higher CD4 cell counts (72). Increasing evidence suggests a reduction in death, opportunistic
infections, serious non-AIDS events and an increase in rates of maximal virologic suppression
and CD4 cell counts in patients who initiate therapy with CD4 counts between 200-350 cells/µL